Shares of Dianthus Therapeutics, Inc. (NASDAQ
NTH - Get Free Report) have received a consensus rating of "Buy" from the eleven analysts that are presently covering the company, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation and two have…Continue reading...